Ibuprofen Lysine Injection

INDICATIONS AND BACKGROUND
Ibuprofen lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1,500 g who are no more than 32 weeks gestational age when usual medical management (fluid restriction, diuretics, respiratory support, etc.) is ineffective. 1 Indomethacin injection is indicated for the treatment of PDA in premature infants weighing between 500 and 1,750 g when, after 48 hours, usual medical management is ineffective. 2 PDA commonly occurs in premature infants with respiratory distress syndrome; 31% of infants weighing between 501 and 1,500 g have PDA. When substantial leftto-right shunting occurs through the ductus there is an increased risk of intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, and death. 3 Previously, intravenous (IV) indomethacin was the only pharmacologic therapy available for the treatment of PDA. However, indomethacin can adversely affect renal, GI, and cerebral perfusion and may cause complications such as transient or permanent renal dysfunction, necrotizing enterocolitis, GI hemorrhage, and reduced cerebral intracellular oxygenation. 3 IV ibuprofen is an alternative to IV indomethacin. In animal models, ibuprofen closed the ductus without affecting basal cerebral blood flow and intestinal or renal hemodynamics during positivepressure ventilation. 3 
CLINICAL PHARMACOLOGY
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin and ibuprofen, are thought to close the ductus arteriosus by reducing the biosynthesis of dilating prostaglandins. 4 
PHARMACOKINETICS
Administration of ibuprofen 10 mg/kg IV over 15 minutes in 27 preterm newborns on day 3 of life produced a peak plasma concentration of 33.3 mg/L. Subsequent administration of ibuprofen 5 mg/kg IV over 15 minutes on day 5 of life produced a peak plasma concentration of 28.4 mg/L. 4 Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. IV ibuprofen is associated with an initial distribution half-life of approximately 1 hour. 4 The mean elimination half-life in preterm neonates is 26 to 43 hours. 4, 5 Ibuprofen clearance in premature infants at birth is 3 mL/kg/h, but increases rapidly with postnatal age (an average increase of approximately 0.5 mL/kg/h per day). 1 Inter-individual variability in clearance is up to 55%. 1, 4 The volume of distribution decreases with closure of the ductus (0.247 to 0.147 L/kg; P = 0.03). No other changes in pharmacokinetic parameters were associated with closure of the ductus. 4 Ibuprofen is metabolized by CYP-450 2C9 and 2C8. 4 In adults, renal elimination of unchanged ibuprofen accounts for 10% to 15% of the dose. 1 In neonates, renal function and the enzymes associated with drug metabolism are underdeveloped at birth, and substantially increase in the days after birth.
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COMPARATIVE EFFICACY
Ibuprofen lysine was assessed in a randomized, double-blind study enrolling 136 premature asymptomatic infants (birth weight 500 to 1,000 g; younger than 30 weeks postconceptual age) with echocardiographic evidence of PDA. Infants received either placebo or ibuprofen (10 mg/kg for the first dose, followed by 5 mg/kg at 24 and 48 hours). The primary study end point was the need for rescue therapy (indomethacin, open-label ibuprofen, or surgical ligation) to treat hemodynamically significant PDA by day 14. Mean birth age was 1.5 days (range, 4.6 to 73 hours), mean gestational age was 26 weeks (range, 23 to 30 weeks), and mean weight was 798 g (range, 530 to 1,015 g). Rescue therapy was required in 17 of 68 (25%) infants treated with ibuprofen, compared with 33 of 68 (48%) treated with placebo (P = 0.003). Significant differences were not observed between the treatment groups for mortality; number of patients on a ventilator or requiring oxygenation at days 1, 4, or 14; number of patients requiring surgical ligation (12%); number of cases of pulmonary hemorrhage or pulmonary hypertension by day 14; or incidence of stage 2/3 necrotizing enterocolitis, grade 3/4 intraventricular hemorrhage, periventricular leukomalacia, or retinopathy of prematurity. 1 IV ibuprofen lysine was compared with IV indomethacin in a randomized study enrolling 148 infants (gestational age, 24 to 32 weeks) with respiratory distress syndrome and an echocardiographically confirmed PDA. Infants were excluded if they had major congenital abnormalities, life-threatening infection or hydrops fetalis, recent intraventricular hemorrhage, urine output below 1 mL/kg/h, serum creatinine of 1.6 mg/dL or greater, blood urea nitrogen (BUN) concentration greater than 40 mg/dL, platelet count of 60,000/mm 3 or less, tendency to bleed, or hyperbilirubinemia requiring exchange transfusion. Eligible infants were randomly assigned at 5 neonatal intensive care centers in Belgium to receive 3 IV doses of either indomethacin (0.2 mg/kg given at 12-hour intervals) or 3 IV doses of ibuprofen (10 mg/kg for the first dose, followed at 24-hour intervals by two 5 mg/kg doses). Therapy was initiated on the third day of life. The rate of ductal closure was 66% with indomethacin (49 of 74 infants) and 70% with ibuprofen (52 of 74 infants; relative risk 0.94; 95% confidence interval [CI], 0.76 to 1.17; P = 0.41). No reopening of the ductus after closure was observed in either group. Survival at 1 month was similar in the 2 groups (P = 0.76), as was rate of survival to discharge, rate of bronchopulmonary dysplasia, proportion needing respiratory support, time required to regain birth weight, time until full enteral feeding was possible, and rate of microscopic hematuria. The number of infants subsequently requiring a second pharmacologic treatment or surgical ductal ligation did not differ between groups. Oliguria occurred in 5 infants treated with ibuprofen and 14 treated with indomethacin (P = 0.03). Urine output was lower from day 3 to day 7 in the indomethacin group than the ibuprofen group (P < 0.001), while the increase in serum creatinine from day 4 to day 8 was greater in the indomethacin group (P = 0.04). 3 Ibuprofen lysine and indomethacin were also compared in a randomized study enrolling 175 preterm infants (23 to 34 weeks gestation) from 2 neonatal intensive care units in Italy with respiratory distress syndrome and persistent, hemodynamically significant PDA at 48 to 72 hours of life. Exclusion criteria included major congenital abnormalities, persistent pulmonary hypertension, recent bleeding, platelet count of 50,000/mm 3 or less, urine output below 1 mL/kg/h, serum creatinine greater than 140 mMol/L, and BUN greater than 14 mMol/L. Eligible infants received 3 doses of indomethacin 0.2 mg/kg IV at 12-hour intervals or 3 doses of ibuprofen (10 mg/kg first dose, followed by 2 doses of 5 mg/kg at 24-hour intervals). Closure at completion of the first course of therapy occurred in 56 of 81 (69%) indomethacin-treated infants and 69 of 94 (73%) ibuprofen-treated infants. Reopening of the ductus occurred in 2 ibuprofen-treated infants, with closure of the ductus after a subsequent course of therapy with the same drug. A total of 25 patients in each group received a further 3 rescue doses of the same medication, achieving closure in 11 cases (44%) with indomethacin and 12 (48%) with ibuprofen. At the end of pharmacologic treatment, closure was achieved in 82% of indomethacintreated infants and 86% of ibuprofen-treated infants. Indomethacin was associated with a greater increase in serum creatinine (89 vs 82 mMol/L; P = 0.03) and greater incidence of oliguria (15% vs 1%; P = 0.017). 6 Ibuprofen lysine was also compared with indomethacin in a randomized study enrolling 63 preterm infants 2 to 7 days of age (birthweight, 1,500 g or less; gestational age, 32 weeks or younger) with respiratory distress syndrome and echocardiographic evidence of PDA. Exclusion criteria were similar to the previously described studies.
Patients received indomethacin 0.2 mg/kg IV every 12 hours for 3 doses or ibuprofen 10 mg/kg for the first dose, followed by 5 mg/kg after 24 and 48 hours. Ductal closure occurred in 27 of 32 (84.4%) patients in the ibuprofen group and 25 of 31 (80.6%) patients in the indomethacin group. Reopening of the ductus occurred in 3 patients in the ibuprofen group (9.4%) and 3 patients in the indomethacin group (9.7%). One patient in the ibuprofen group and 2 patients in the indomethacin group required ductal ligation. Ibuprofen-treated infants had lower serum creatinine (P < 0.01) and BUN (P < 0.05) concentrations, and higher urine output (P < 0.02) and creatinine clearance (P < 0.01) than the group treated with indomethacin. Gastric bleeding occurred in 2 patients in the indomethacin group. There were no significant differences between treatment groups in the rates of intraventricular hemorrhage, necrotizing enterocolitis, duration of ventilation, duration of neonatal intensive care unit or hospital stay, or time to regain birth weight. 7 Another randomized study conducted in Belgium compared IV indomethacin and ibuprofen in 40 preterm infants (gestational age, younger than 33 weeks) with respiratory distress syndrome and echocardiographically confirmed PDA. Exclusion criteria were similar to the previously described studies. At 2 to 3 days of life, infants received indomethacin 0.2 mg/kg IV every 12 hours for 3 doses or ibuprofen 10 mg/kg for one dose, followed by 5 mg/kg after 24 and 48 hours. Ductal closure occurred in 15 of 20 (75%) patients in the indomethacin group and 16 of 20 (80%) in the ibuprofen group. Seven patients (3 in the indomethacin group and 4 in the ibuprofen group) required a second treatment with indomethacin and 5 patients (3 in the indomethacin group and 2 in the ibuprofen group) ultimately required ductal ligation. Patients in the ibuprofen group had greater urinary output and showed no increase in serum creatinine, compared with the indomethacin group. Oliguria developed in 40% of indomethacin-treated infants, compared with 5% of ibuprofentreated infants (P = 0.02). 8 Another double-blind, dosefinding study attempted to determine the lowest effective dose regimen of ibuprofen lysine required to close ductus arteriosus in preterm infants. Goal closure rates were 80% for infants with postmenstrual age of 27 to 29 weeks and 50% in infants with a postmenstrual age of younger than 27 weeks. Twenty infants in each age group with PDA were treated between days 3 and 5 of life. Four dose regimens were studied: loading doses of 5, 10, 15, or 20 mg/kg, followed by 2 doses (half the loading dose) at 24 hour intervals. In infants with postmenstrual age of 27 to 29 weeks, the minimum effective dose regimen was the 10 mg/kg loading dose followed by two 5 mg/kg doses, with a final estimated probability of success of 77%. The 15 mg/kg loading dose, followed by two 7.5 mg/kg doses had a better estimated probability of success (88%), but resulted in more minor renal adverse reactions. In infants younger than 27 weeks postmenstrual age, the estimated minimum effective dose was 20 mg/kg as a loading dose followed by two 10 mg/kg doses, with an estimated probability of success of 54.8%. The conventional 10 mg/kg regimen had an estimated success rate of 30.6%. Minor renal adverse reactions were more frequent in this age group from the 10 mg/kg regimen and did not appear to be clearly dose related. Additional studies assessing higher doses in this younger age group are necessary. 9 In an additional pharmacokinetic study assessing IV ibuprofen lysine on days 3, 4, and 5 of life at 24-hour intervals for closure of PDA in 27 preterm infants (mean gestational age, 28.6 + 1.9 weeks), closure of the ductus was achieved in 17 infants (63%). Infants received ibuprofen 10 mg/kg for the first dose and 5 mg/kg for the subsequent 2 doses. From the third to fifth day of life, respiratory status improved in all patients, as reflected by decreasing supplemental oxygen requirements (from 42% to 30%; P < 0.001) and lower mean airway pressures (from 10 to 8.2 cm H 2 O; P < 0.001). Systemic mean blood pressure and serum creatinine, serum albumin, and total serum bilirubin concentrations remained stable during treatment. 4 Several additional studies assessed the effects of ibuprofen and indomethacin on cerebral perfusion and oxygenation, mesenteric blood flow, and renal blood flow in preterm infants with PDA. 10, 11, 12 Overall, compared with indomethacin, ibuprofen was associated with fewer reductions in cerebral perfusion and oxygenation, mesenteric blood flow, and renal blood flow. 10, 11, 12 In 16 infants treated with indomethacin 0.2 mg/kg or ibuprofen 10 mg/kg infused over 1 minute, indomethacin caused a reduction in cerebral blood volume, cerebral blood flow velocity, and oxygen availability. Ibuprofen caused no change in cerebral blood flow velocity or oxygen availability, but was associated with an increase in cerebral blood volume. Ductus closure occurred in 6 of 8 infants after the first dose of indomethacin and 5 of 8 infants after the first dose of ibuprofen. 10 In another study including 33 preterm infants with PDA, indomethacin was associated with reduced cerebral blood flow, cerebral blood volume, and cerebral oxygen delivery, while ibuprofen was not. 11 In 17 mechanically ventilated preterm infants (younger than 33 weeks gestation) treated with either indomethacin 0.2 mg/kg or ibuprofen 10 mg/kg infused over 15 minutes, indomethacin was associated with reductions in mesenteric and renal blood flow velocity, while ibuprofen was not. 12 In another study, ibuprofen did not modify urinary antidiuretic hormone (ADH) excretion or urinary sodium and fractional sodium excretion, while indomethacin reduced urinary ADH excretion and reduced urinary sodium and fractional sodium excretion. 13 However, ibuprofen was shown to reduce glomerular filtration rate to a similar extent as acetylsalicylic acid in another study including 142 preterm neonates. 14 In addition to numerous studies assessing the efficacy of ibuprofen in the treatment of PDA in preterm infants, several studies also assessed prophylactic administration of ibuprofen lysine within hours of birth in preterm neonates. 15, 16, 17, 18 Although in several studies prophylactic administration reduced the occurrence of PDA and need for additional therapy, it has not been demonstrated to reduce either mortality or morbidity and exhibits no advantage over treatment with ibuprofen lysine. 15, 16, 17, 18 Without prophylactic therapy, ductal closure had occurred spontaneously by day 3 in 60% of infants in these studies. Prophylactic ibuprofen lysine administration exposes these infants to potential side effects without clear benefits. 19 Pulmonary hypertension prompted discontinuation of one study of prophylactic ibuprofen lysine in very preterm infants.
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CONTRAINDICATIONS
Ibuprofen lysine and indomethacin injection are both contraindicated in preterm infants with: 1, 2 • proven or suspected infection that is untreated, • congenital heart disease for which patency of the PDA is necessary for satisfactory pulmonary or systemic blood flow, • bleeding, especially active intracranial hemorrhage or GI bleeding, • thrombocytopenia, • coagulation defects,
• known or suspected necrotizing enterocolitis, or • significant impairment of renal function.
WARNINGS AND PRECAUTIONS
The long-term effects of therapy with ibuprofen lysine on neurodevelopmental outcome and growth or disease processes associated with prematurity have not been assessed. 1 Ibuprofen may alter the usual signs of infection. Infants with, or at risk for, infection should be closely monitored. 1 Ibuprofen, like other NSAIDs, can inhibit platelet aggregation. Preterm infants should be observed for signs of bleeding. Ibuprofen has been shown to prolong bleeding time in normal adults. Bleeding time may be further prolonged in patients with underlying hemostatic defects. Ibuprofen is contraindicated in infants with active bleeding or coagulation defects. 1 Ibuprofen displaces bilirubin from albumin binding sites. It should be used with caution in patients with elevated total bilirubin. 1 Care should be taken to avoid extravascular injection or leakage, as the solution may be irritating to tissue.
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ADVERSE REACTIONS
The most common adverse reactions observed in the placebocontrolled study with ibuprofen lysine included sepsis, anemia, bleeding, apnea, GI disorders, renal events, respiratory infection, skin irritation, hypoglycemia, hypocalcemia, and respiratory failure (see Table 1 ). 1 Compared with placebo, ibuprofen lysine was associated with a small reduction in urinary output on days 2 to 6 of life, with a compensatory increase in urine output on day 9. In other studies, adverse reactions observed in ibuprofen lysine-treated neonates included oliguria, elevated BUN, elevated creatinine, and renal failure. 
DRUG INTERACTIONS
Coadministration of ibuprofen lysine with amikacin in preterm neonates resulted in an increased amikacin half-life (16.4 vs 12.4 hours; P < 0.02) and reduced amikacin clearance (0.36 vs 0.6 mL/kg/min; P < 0.005), compared with administration of amikacin alone. 21 Further drug interactions have not been assessed. 1 As with other NSAIDs, there is the potential for interactions with other medications that affect bleeding or renal function.
RECOMMENDED MONITORING
Patients should be closely observed for signs of bleeding or infection.
DOSING
A course of therapy consists of 3 doses of ibuprofen lysine administered at 24-hour intervals. The initial dose of ibuprofen is 10 mg/kg, followed by 2 doses of 5 mg/kg at 24 and 48 hours. All doses should be based on birth weight. If anuria or marked oliguria (urinary output less than 0.6 mL/kg/h) is evident at the scheduled time of the second or third dose, no additional doses should be administered until renal function has returned to normal. If the ductus arteriosus closes or is significantly reduced in size after completion of the first course of therapy, no further doses are necessary. If during continued medical management the ductus fails to close or reopens, then a second course of ibuprofen lysine, alternative pharmacologic therapy (eg, indomethacin), or surgery may be necessary. 1 Ibuprofen lysine solution should be diluted to an appropriate volume with dextrose or saline. The injection should be prepared for infusion, administered within 30 minutes of preparation, and infused continuously over 15 minutes. The drug should be administered via the IV port nearest the insertion site. Administration via an umbilical arterial line has not been evaluated. Care should be taken to avoid extravasation. 1 Ibuprofen lysine should not be simultaneously administered in the same IV line with total parenteral nutrition. If necessary, total parenteral nutrition should be interrupted for a 15-minute period prior to and after drug administration. Line patency should be maintained using dextrose or saline. water-soluble formulation suitable for IV administration. Each mL of the injectable solution contains 17.1 mg of ibuprofen lysine (equivalent to 10 mg of ibuprofen) in water for injection. It is supplied in cartons containing 3 single-use glass vials, each containing 2 mL of the sterile, preservative-free solution. 1 The pH is adjusted to 7 with sodium hydroxide or hydrochloric acid. 1 Ibuprofen lysine should be stored at controlled room temperature (20º to 25ºC; 68º to 77ºF), with excursions permitted to 15º to 30ºC (59º to 86ºF). 1 Stability is enhanced when the injection solution is protected from light. 22 The vials should be stored in the carton until the contents have been used.
1
CONCLUSION
Ibuprofen lysine appears as effective as indomethacin injection for the treatment of asymptomatic PDA in preterm neonates. Ibuprofen has been associated with a lower risk of oliguria during therapy; however, no advantage with regard to survival or other longterm outcomes associated with prematurity were observed in the clinical trials. 
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